相关实验视频

Updated: Jun 18, 2025

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

对CEA进行个性化参考间隔的临床实用性,用于早期发现瘤疾病

Débora Martínez-Espartosa¹, Estíbaliz Alegre^2,3, Hugo Casero-Ramírez⁴

¹Biochemistry Department, Clínica Universidad de Navarra, Madrid, Spain.

Clinical chemistry and laboratory medicine

|August 5, 2024

概括

个性化参考间隔 (prRI) 显示高灵敏度和癌症检测的负预测值. 这种方法有效地排除了患者监测期间的新瘤发现.

科学领域:

临床化学临床化学
在瘤学瘤学.
生物标志物的分析分析.

背景情况:

建议个性化参考间隔 (prRI) 用于评估个体测量和测量.
癌胚抗原 (CEA) 是癌症检测中的一个关键生物标志物.
将prRI与参考变化值 (RCV) 等既定标准进行评估至关重要.

研究的目的:

用CEA评估prRI用于癌症检测的临床性能.
将prRI与RCV,RV25和CP5标准进行比较.
为了确定prRI在癌症监测中的诊断准确性.

主要方法:

在19年间对2638名患者的临床和分析数据进行了回顾性分析 (15,485名CEA结果).
使用算法计算prRI和RCV,考虑个人内生物变异的各种策略 (CV_I-EU,CV_I-NOO,CV_P).
通过跟踪每个策略的瘤存在后测试来评估灵敏度,特异性和预测能力.

主要成果:

使用CV_I-EU和两个参考区间极限的prRI方法在3个月和12个月时显示出最高的灵敏度 (87.5%) 和负预测值 (99.3%).
只有三个患者的CEA结果足以实现pr.RI的诊断性能.
在癌症检测准确度方面,prRI的表现优于其他评估标准.

结论:

prRI方法是排除新瘤发现的有效工具.
这些个性化间隔增强了对癌症患者的积极监测.
prRI为改善癌症监测和诊断提供了一个有希望的策略.

关键词:

在 CEA CEA 中.生物变异生物变异癌症癌症癌症癌症癌症个性化的参考间隔.参考价值变化参考价值的变化参考时间间隔的参考时间间隔.

更多相关视频

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...